Compare NOVT & BLLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NOVT | BLLN |
|---|---|---|
| Founded | 1968 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Medical Specialities |
| Sector | Miscellaneous | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.0B | 4.6B |
| IPO Year | 1999 | 2025 |
| Metric | NOVT | BLLN |
|---|---|---|
| Price | $168.75 | $93.91 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 1 | 7 |
| Target Price | ★ $144.00 | $126.71 |
| AVG Volume (30 Days) | 412.9K | ★ 795.0K |
| Earning Date | 05-11-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 103.40 |
| EPS | ★ 0.82 | 0.48 |
| Revenue | ★ $521,290,000.00 | $305,112,000.00 |
| Revenue This Year | $8.61 | $46.29 |
| Revenue Next Year | $6.57 | $30.14 |
| P/E Ratio | $203.15 | ★ $194.44 |
| Revenue Growth | 35.49 | ★ 99.97 |
| 52 Week Low | $98.27 | $61.96 |
| 52 Week High | $176.38 | $150.44 |
| Indicator | NOVT | BLLN |
|---|---|---|
| Relative Strength Index (RSI) | 61.45 | 37.20 |
| Support Level | $146.45 | $73.46 |
| Resistance Level | $167.79 | $99.29 |
| Average True Range (ATR) | 6.35 | 6.90 |
| MACD | 1.97 | -4.42 |
| Stochastic Oscillator | 74.05 | 11.29 |
Novanta Inc supplies core technology solutions to medical, life science, and advanced industrial OEMs, leveraging proprietary expertise in precision medicine, precision manufacturing, robotics and automation, and advanced surgery. It has two segments: Automation Enabling Technologies and Medical Solutions. Automation Enabling Technologies, which generates the majority of revenue, provides laser beam steering and scanning solutions, laser sources, and robotic and precision motion technologies. The Medical Solutions segment provides medical-grade technologies, including medical insufflators, endoscopic pumps, and integrated operating room technologies. The company operates in the United States, Germany, and other markets, with revenue generated from the United States.
BillionToOne Inc is a molecular diagnostics company. It offers a portfolio of ultrasensitive tests covering prenatal genetic testing, cancer therapy selection, and response monitoring, which are based on its Quantitative Counting Templates (QCT) molecular counting platform. The company's product portfolio comprises UNITY, a portfolio of prenatal testing products that can conduct fetal risk analysis without requiring a paternal sample; Northstar Select, a ultrasensitive liquid biopsy test that provides insights into appropriate therapies for stage III or IV cancer patients; and Northstar Response, a tissue-free, pan-cancer, liquid biopsy test that measures several genomic loci uniquely methylated in cancer to provide insight into dynamic changes in therapy response.